Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus
Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.